Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

There has been extensive progress in understanding the cellular and molecular
mechanisms of inflammation and immune regulation in allergic diseases of the skin and …

Background In some patients with chronic obstructive pulmonary disease (COPD), type 2
inflammation may increase exacerbation risk and may be indicated by elevated blood …

Background Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and
interleukin-13 signaling, which have key roles in eosinophilic esophagitis. Methods We …

Background Dupilumab is a human monoclonal antibody that blocks interleukin-4 and
interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by …

Background Children with moderate-to-severe asthma continue to have disease
complications despite the receipt of standard-of-care therapy. The monoclonal antibody …

Background Clinical trials have shown treatment benefits of dupilumab in patients with
uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and …

Background Transient increases in blood eosinophil counts have been observed in
dupilumab clinical trials. Objective To assess eosinophil counts and eosinophilia-related …

Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …